Dual GLP-1/GIP agonist challenger
Viking Therapeutics is a California biotech developing VK2735, a dual GLP-1/GIP receptor agonist peptide showing best-in-class weight loss in early trials. Viking is also developing an oral version, positioning it as a credible challenger to Novo Nordisk and Eli Lilly in the obesity peptide race.
| Drug / Program | Indication | Phase | Technology |
|---|---|---|---|
| VK2735 (SC) | Obesity | Phase 3 | GLP-1/GIP Dual Agonist |
| VK2735 (Oral) | Obesity | Phase 2 | Oral GLP-1/GIP |
| VK2809 | NASH | Phase 2 | THR-β agonist |
How to invest in the peptide therapeutics boom via ETFs and funds. Obesity-themed, broad biotech, and pharma mega-cap options compared for 2026.
A comprehensive look at the CRISPR companies shaping the future of medicine in 2026, from approved therapies to next-generation editing platforms.